Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
O6-benzylguanine + BCNU in Recurrent Glioma
NCT00005081Phase 2Completed
- Sponsor
- Duke University
- Start
- Aug 2000
- Primary completion
- Apr 2001
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 6-benzylguanine in glioblastoma multiforme (GBM), anaplastic astrocytoma (AA) and Gliosarcoma (GS), sponsored by Duke University. Primary endpoints: Antitumor Activity and Toxic Effects. Started Aug 2000; status: completed.
02
Drugs
6-benzylguanine
03
Conditions
glioblastoma multiforme (GBM)anaplastic astrocytoma (AA)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00005081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005081.